2022-07-05-世界卫生组织-Immunization_Andorra_2022_country_profile_16页_332kb

报告摘要

Summary of Andorra Immunization Coverage Estimates (WHO and UNICEF, 2021 Revision)

Overview

This summary outlines WHO and UNICEF's estimated national immunization coverage for Andorra, based on data up to July 7, 2022. The estimates focus on key vaccines such as BCG, DTP, polio, measles, hepatitis B, and others, for the years 2010 to 2021. Coverage data is derived primarily from national government reports, with confidence levels (GoC) indicating the quality of supporting evidence. Estimates are cautious due to potential data biases and should be assessed contextually.

Methodology

Estimates rely on reported data from Andorra's health authorities, interpolated surveys, or external recalculations.
Grade of Confidence (GoC) categories reflect empirical support:
- •••: Well-supported by multiple data sources (high confidence).
- ••: Supported by at least one data source, no challenges (medium confidence).
- No accepted empirical data: Data challenged or inadequate (low confidence).
Background includes expert review and consideration of global immunization schedules, with notes on potential inaccuracies in numerator/denominator data.

Key Findings by Vaccine

High and Consistent Coverage for Multiple Vaccines

DTP Series and Polio-Related Vaccines (DTP1, DTP3, Pol3, IPV1): Coverage ranges from 95% to 100% across most years (2010-2021), with exceptions like lower values in early 2010s. DTP1 and DTP3 estimates based on other series, showing steady high coverage post-2005. GoC is typically R+ (reported data, no challenge).
Measles-Related Vaccines (MCV1, MCV2): Coverage around 85-100%, with MCV1 stabilizing post-2010. Some years show no independent assessment, but general levels are high. MCV2 coverage dipped in reported data but is still reliable.
Other Vaccines (MCV1, RCV1, HepBB, HepB3, Hib3, RotaC, PcV3): HepBB, HepB3, Hib3, and RCV1 show high coverage (>90%) where data exists, often aligned with other estimates. HepB was removed from the schedule in 2017 but remained high until then. RotaC and PcV3 have sparsely covered data, with recent estimates averaging ~95-98%.

Trends and Characteristics

Consistency: Most vaccines show stable high coverage from 2010 onwards, reflecting Andorra's likely robust immunization system, though data gaps exist.
Confidence Levels: Most estimates are R+ (reliant on reported data), with no widely accepted empirical assessments in recent years. Older data (2000s) often lacked supporting evidence.
Limitations: No accepted empirical data for some years, raising caution. All estimates carry risks of bias and should be used with care.